Daily low-dose aspirin reduced the risk for colorectal cancer recurrence by roughly half in patients with mutations in the ...

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance ...

SAN FRANCISCO -- In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on ...

Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in the PI3K ...

Adjuvant treatment with 160 mg aspirin daily for three years cuts recurrence rates in patients with colorectal cancer.

Three-year results from the ALASCCA trial (NCT02647099), presented at the 2025 ASCO Gastrointestinal Cancer Symposium, showed ...

Adjuvant treatment with aspirin is associated with a lower risk of recurrence at 3 years in CRC patients with PI3K pathway ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...